钠葡萄糖共同转运体-2抑制剂对2型糖尿病脂代谢的影响

Effect of sodium-glucose cotransporter-2 inhibitor on lipid metabolism in type 2 diabetes mellitus

摘要:

2型糖尿病（type 2 diabetes mellitus，T2DM）患者发生动脉粥样硬化性心血管疾病（atherosclerosis-associated cardiovas－cular disease，ASCVD）的危险相比非糖尿病患者明显升高。脂代谢异常与糖代谢异常合并，均为ASCVD的危险因素和发病机制。钠葡萄糖共同转运体-2抑制剂（sodium-glucose cotransporter-2 inhibitor，SGLT-2i）是一种通过肾脏排泄葡萄糖的新型降糖药。近年来多项大型临床研究表明SGLT-2i具有心血管和肾脏获益，但机制尚不明确。本文综述了SGLT-2i对T2DM中的脂代谢影响，分析其与上述保护作用之间的可能关系。

Abstract:

The risk of arteriosclerotic cardiovascular disease（ASCVD） in patients with type 2 diabetes mellitus（T2DM） is significantly higher than that in non-diabetic patients. Abnormal lipid metabolism and abnormal glucose metabolism are risk factors and pathogen－esis of ASCVD. The sodium-glucose cotransporter-2 inhibitor（SGLT-2i） is a new type of hypoglycemic agent excreting glucose via kidneys. Recent large clinical trials have shown that SGLT-2i shows significant cardiovascular and kidney benefits，but its mechanism remains unclear. This article reviewed effects of SGLT-2 inhibition on lipid metabolism in T2DM and analyzed its possible relation－ship with above protective effects.